- Home
- Pathology Industry
- All premium reports
- Lung Cancer Analysis & Statistics, May 2013
Industries
- Pathology (3 739)
- In Vitro Diagnostic (81)
- Therapy (63)
- Drug and Medication (56)
- Medical Equipment and Supply (33)
-
- Diagnostics (31)
- Drug Discovery and Development (29)
- Genomics (29)
- Pharmaceutical (25)
- Generic Drug (21)
- Medical Imaging (16)
- Biotechnology (15)
- General Medicine and Specialty Medicine (9)
- Biopharmaceutical (7)
- Biological Therapy (6)
- Healthcare (3)
- Blood Supply, Tissue Banking and Transplantation (2)
- Drug Delivery Technology (2)
- Juice (2)
- Managed Care (2)
Top countries
- United States (307)
- World (585)
- Japan (75)
- Europe (52)
- Germany (75)
-
- France (70)
- Italy (68)
- Spain (67)
- United Kingdom (65)
- Canada (40)
- China (39)
- Australia (31)
- India (26)
- North America (8)
- Israel (29)
- South Korea (28)
- South America (5)
- Denmark (24)
- Greece (26)
- Russian Federation (27)
Publication dates
Publishers
- Global Data (286)
- Global Markets Direct (105)
- Bioseeker (94)
- Venture Planning Group (67)
- BCC Research (18)
-
- GBI Research (18)
- Datamonitor (14)
- TriMark Publications (12)
- Espicom Business Intelligence (10)
- Global Industry Analyst (8)
- Kalorama Information (8)
- GenericsWeb - Selector 7 (7)
- Generics Web - Selector 44 (7)
- GenericsWeb (6)
- SCRIP Insights (6)
- Currentpartnering (5)
- MarketsandMarkets (5)
- The Assessment Group (5)
- Visiongain (5)
- BioPharm Reports (4)
- Frost & Sullivan (4)
- Koncept Analytics (4)
- Industry Experts (3)
- Apollo Managed Care Consultants (2)
- Arrowhead (2)
- Asia Market Information & Development Company (2)
- Axis Research Mind (2)
- CHI Insight Pharma Reports (2)
- ICD Research (2)
- Infiniti Research Limited (2)
- RNCOS (2)
- Timely Data Resources Inc. (2)
- Aruvian's R'search (1)
- CCM International Limited (1)
- Firstword Pharma (1)
- Freedonia (1)
- Huidian Research (1)
- Life Science Analytics (LSA) (1)
- Netscribes (India) Pvt. Ltd. (1)
- Renub Research (1)
- Timetric (1)
- Business Monitor International (3 414)
All regions
-
- Algeria (21)
- Angola (21)
- Benin (16)
- Botswana (15)
- Burkina Faso (20)
- Burundi (16)
- Cameroon (20)
- Cape Verde (15)
- Central African Republic (1)
- Chad (19)
- Comoros (15)
- Congo, Democratic Republic Of (23)
- Djibouti (15)
- Egypt (25)
- Equatorial Guinea (15)
- Eritrea (15)
- Ethiopia (21)
- Gabon (15)
- Gambia (15)
- Ghana (20)
- Guinea (50)
- Guinea Bissau (15)
- Kenya (16)
- Lesotho (15)
- Liberia (15)
- Libyan Arab Jamahiriya (17)
- Madagascar (18)
- Malawi (16)
- Mali (20)
- Mauritania (15)
- Mauritius (15)
- Morocco (22)
- Mozambique (17)
- Namibia (15)
- Niger (20)
- Nigeria (21)
- Rwanda (15)
- Sao Tome and Principe (15)
- Senegal (18)
- Seychelles (15)
- Sierra Leone (16)
- Somalia (15)
- South Africa (23)
- Sudan (17)
- Swaziland (15)
- Tanzania (15)
- Togo (16)
- Tunisia (20)
- Uganda (20)
- Zambia (20)
- Zimbabwe (20)
-
- Afghanistan (20)
- Armenia (22)
- Azerbaijan (23)
- Bahrain (15)
- Bangladesh (18)
- Bhutan (15)
- Brunei Darussalam (15)
- Cambodia (16)
- China (39)
- Georgia (23)
- India (26)
- Indonesia (19)
- Iran (23)
- Iraq (23)
- Israel (29)
- Japan (75)
- Jordan (18)
- Kazakhstan (24)
- Kuwait (15)
- Kyrgyz Republic (kyrgyzstan) (20)
- Laos (15)
- Lebanon (17)
- Malaysia (19)
- Maldives (15)
- Mongolia (1)
- Myanmar (16)
- Nepal (15)
- North Korea (1)
- Oman (15)
- Pakistan (23)
- Philippines (23)
- Qatar (15)
- Saudi Arabia (20)
- Singapore (17)
- South Korea (28)
- Sri Lanka (15)
- Syrian Arab Republic (20)
- Taiwan (1)
- Tajikistan (16)
- Thailand (20)
- Turkmenistan (1)
- United Arab Emirates (15)
- Uzbekistan (23)
- Vietnam (21)
- Yemen (23)
-
- Albania (20)
- Andorra (15)
- Austria (21)
- Belarus (23)
- Belgium (23)
- Bosnia and Herzegovina (21)
- Bulgaria (21)
- Croatia (21)
- Cyprus (15)
- Czech Republic (23)
- Denmark (24)
- Estonia (17)
- Finland (19)
- France (70)
- Germany (75)
- Greece (26)
- Hungary (24)
- Iceland (15)
- Ireland (20)
- Italy (68)
- Latvia (18)
- Lithuania (20)
- Luxembourg (15)
- Macedonia (1)
- Malta (15)
- Moldova, Republic Of (19)
- Monaco (15)
- Netherlands (24)
- Norway (20)
- Poland (26)
- Portugal (23)
- Romania (24)
- Russian Federation (27)
- San Marino (15)
- Serbia and Montenegro (23)
- Slovakia (slovak Republic) (21)
- Slovenia (17)
- Spain (67)
- Sweden (23)
- Switzerland (22)
- Ukraine (24)
- United Kingdom (65)
-
- Antigua and Barbuda (15)
- Bahamas (15)
- Barbados (15)
- Belize (15)
- Canada (40)
- Costa Rica (15)
- Cuba (19)
- Dominica (16)
- Dominican Republic (15)
- El Salvador (15)
- Grenada (15)
- Guatemala (15)
- Haiti (15)
- Honduras (15)
- Jamaica (15)
- Mexico (24)
- Nicaragua (15)
- Panama (15)
- Saint Kitts & Nevis (15)
- Saint Lucia (15)
- United States (307)
-
- Australia (31)
- Austria (21)
- Belgium (23)
- Canada (40)
- Chile (19)
- Czech Republic (23)
- Denmark (24)
- Estonia (17)
- Finland (19)
- France (70)
- Germany (75)
- Greece (26)
- Hungary (24)
- Iceland (15)
- Ireland (20)
- Israel (29)
- Italy (68)
- Japan (75)
- Luxembourg (15)
- Mexico (24)
- Netherlands (24)
- New Zealand (16)
- Norway (20)
- Poland (26)
- Portugal (23)
- Slovenia (17)
- South Korea (28)
- Spain (67)
- Sweden (23)
- Switzerland (22)
- United Kingdom (65)
- United States (307)
data types
» Purchase Premium Reports
1-20 of about 4 100 reports for Lung Cancer
Lung Cancer - Pipeline Review, Q1 2011
- $ 500
- Company report
- January 2011
- by Global Markets Direct
... And deals relating to the products.Reasons to buy- identify and understand important and diverse types of therapeutics under development for lung cancer.- Identify emerging players ...
- Industries : Drug and Medication, Healthcare, Pharmaceutical
- Countries : United States
South Korea Trachea, Bronchus, Lung Cancers, Dalys
- $ 250
- Industry data
- March 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : South Korea
Brazil Trachea, Bronchus, Lung Cancers, Dalys
- $ 250
- Industry data
- March 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
North Korea Trachea, Bronchus, Lung Cancers, Dalys
- $ 250
- Industry data
- March 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : North Korea, South Korea
Canada Trachea, Bronchus, Lung Cancers, Dalys
- $ 250
- Industry data
- March 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
Australia Trachea, Bronchus, Lung Cancers, Dalys
- $ 250
- Industry data
- March 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
Singapore Trachea, Bronchus, Lung Cancers, Dalys
- $ 250
- Industry data
- March 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
United States Trachea, Bronchus, Lung Cancers, Dalys
- $ 250
- Industry data
- March 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : United States
France Trachea, Bronchus, Lung Cancers, Dalys
- $ 250
- Industry data
- March 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
United Kingdom Trachea, Bronchus, Lung Cancers, Dalys
- $ 250
- Industry data
- March 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
- Industries : Pathology
- Countries : United Kingdom
Lung Cancer - Pipeline Review, H1 2013
- $ 2 000
- Company report
- April 2013
- by Global Markets Direct
... Relating to the products. Reasons to buy - identify and understand important and diverse types of therapeutics under development for lung cancer.- Identify emerging players ...
- Industries : Pathology
France Trachea, Bronchus, Lung Cancers, Total, Male, Dalys
- $ 250
- Industry data
- May 2013
Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research
Lung Cancer - Pipeline Review, Q1 2011
- $ 500
- Company report
- January 2011
- by Global Markets Direct
... And deals relating to the products.Reasons to buy- identify and understand important and diverse types of therapeutics under development for lung cancer.- Identify emerging players ...
- Industries : Drug and Medication, Healthcare, Pharmaceutical
- Countries : United States
Metastatic Lung Cancer - Pipeline Review, Q4 2010
- $ 500
- Company report
- December 2010
- by Global Markets Direct
... Provides an overview of the metastatic lung cancer therapeutic pipeline. This report provides information on the therapeutic development for metastatic lung cancer , complete with latest updates ...
Lung Cancer - Pipeline Review, Q3 2011
- $ 500
- Company report
- July 2011
- by Global Markets Direct
... Reasons to buy- identify and understand important and diverse types of therapeutics under development for lung cancer.- Identify emerging players with potentially strong product portfolio ...
- Industries : Pathology
- Countries : United States
Lung Cancer Clinical Trials Review, Q4 2010
- $ 1 000
- Industry report
- November 2010
- by Global Data
... Provides in-depth information and data relating to the clinical trials on lung cancer . It includes an overview of the trial numbers and their recruitment status as per the site of trial development ...
- Industries : Drug Discovery and Development, Pathology
- Countries : World, North America, Europe, South America
Metastatic Lung Cancer - Pipeline Review, H1 2013
- $ 2 000
- Company report
- April 2013
- by Global Markets Direct
... Of development ranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the metastatic lung cancer pipeline ...
- Industries : Pathology
- Countries : World, United States, Canada
Metastatic Lung Cancer - Pipeline Review, Q2 2011
- $ 500
- Industry report
- April 2011
- by Global Markets Direct
... From discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the metastatic lung cancer pipeline on the basis ...
Metastatic Lung Cancer - Pipeline Review, H2 2011
- $ 500
- Industry report
- August 2011
- by Global Markets Direct
... cancer therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential ...
Lung Cancer Global Clinical Trials Review, Q4, 2010
- $ 1 000
- Industry report
- December 2010
- by Global Data
... Of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides information pertaining to the number of trials for the key drugs for treating lung cancer ...
- Industries : Drug Discovery and Development
- Countries : World
» Download Public Reports
About 4 800 reports for Lung Cancer
The Chinese Lung Cancer Industry
- Industry report
- May 2010
- 32 pages
U.s. Tobacco Industry Analysis
August 2010Cancer Sector Analysis In The United States
November 2011Cancer Sector Analysis In Canada And Italy
November 2010» Read our Company Profiles
36 Companies for Lung CancerCepheid
United StatesTaliaferro and Browne Inc.
United StatesUnicel
United StatesEiken Chemical
JapanGlaxoSmithKline P.L.C.
United StatesReportlinker.com © Copyright 2013. All rights reserved.
